Effect of dexamethasone in patients with ARDS and COVID-19-prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F21%3AA2302FAR" target="_blank" >RIV/61988987:17110/21:A2302FAR - isvavai.cz</a>
Alternative codes found
RIV/61383082:_____/21:00001126 RIV/00159816:_____/21:00074413 RIV/00216224:14110/21:00121476 RIV/00216208:11120/21:43921221 and 10 more
Result on the web
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:000625387800002" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:000625387800002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s13063-021-05116-9" target="_blank" >10.1186/s13063-021-05116-9</a>
Alternative languages
Result language
angličtina
Original language name
Effect of dexamethasone in patients with ARDS and COVID-19-prospective, multi-centre, open-label, parallel-group, randomised controlled trial (REMED trial): A structured summary of a study protocol for a randomised controlled trial
Original language description
Objectives: The primary objective of this study is to test the hypothesis that administration of dexamethasone 20 mg is superior to a 6 mg dose in adult patients with moderate or severe ARDS due to confirmed COVID-19. The secondary objective is to investigate the efficacy and safety of dexamethasone 20 mg versus dexamethasone 6 mg. The exploratory objective of this study is to assess long-term consequences on mortality and quality of life at 180 and 360 days. Trial design: REMED is a prospective, phase II, open-label, randomised controlled trial testing superiority of dexamethasone 20 mg vs 6 mg. The trial aims to be pragmatic, i.e. designed to evaluate the effectiveness of the intervention in conditions that are close to real-life routine clinical practice. Participants: The study is multi-centre and will be conducted in the intensive care units (ICUs) of ten university hospitals in the Czech Republic.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30230 - Other clinical medicine subjects
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
TRIALS
ISSN
1745-6215
e-ISSN
—
Volume of the periodical
—
Issue of the periodical within the volume
1
Country of publishing house
GB - UNITED KINGDOM
Number of pages
4
Pages from-to
—
UT code for WoS article
000625387800002
EID of the result in the Scopus database
—